Day One Biopharmaceuticals (DAWN) Competitors $6.62 +0.05 (+0.76%) Closing price 04:00 PM EasternExtended Trading$6.62 0.00 (-0.08%) As of 04:21 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock DAWN vs. HCM, AMRX, CPRX, BHC, OGN, XENE, MIRM, IBRX, GMTX, and ARWRShould you be buying Day One Biopharmaceuticals stock or one of its competitors? The main competitors of Day One Biopharmaceuticals include HUTCHMED (HCM), Amneal Pharmaceuticals (AMRX), Catalyst Pharmaceuticals (CPRX), Bausch Health Cos (BHC), Organon & Co. (OGN), Xenon Pharmaceuticals (XENE), Mirum Pharmaceuticals (MIRM), ImmunityBio (IBRX), Gemini Therapeutics (GMTX), and Arrowhead Pharmaceuticals (ARWR). These companies are all part of the "pharmaceutical products" industry. Day One Biopharmaceuticals vs. Its Competitors HUTCHMED Amneal Pharmaceuticals Catalyst Pharmaceuticals Bausch Health Cos Organon & Co. Xenon Pharmaceuticals Mirum Pharmaceuticals ImmunityBio Gemini Therapeutics Arrowhead Pharmaceuticals HUTCHMED (NASDAQ:HCM) and Day One Biopharmaceuticals (NASDAQ:DAWN) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, risk, media sentiment, analyst recommendations and valuation. Does the media favor HCM or DAWN? In the previous week, Day One Biopharmaceuticals had 1 more articles in the media than HUTCHMED. MarketBeat recorded 2 mentions for Day One Biopharmaceuticals and 1 mentions for HUTCHMED. HUTCHMED's average media sentiment score of 1.47 beat Day One Biopharmaceuticals' score of 0.63 indicating that HUTCHMED is being referred to more favorably in the media. Company Overall Sentiment HUTCHMED Positive Day One Biopharmaceuticals Positive Which has more risk and volatility, HCM or DAWN? HUTCHMED has a beta of 0.52, indicating that its stock price is 48% less volatile than the S&P 500. Comparatively, Day One Biopharmaceuticals has a beta of -1.27, indicating that its stock price is 227% less volatile than the S&P 500. Do analysts recommend HCM or DAWN? HUTCHMED presently has a consensus target price of $19.00, suggesting a potential upside of 10.92%. Day One Biopharmaceuticals has a consensus target price of $29.00, suggesting a potential upside of 338.07%. Given Day One Biopharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Day One Biopharmaceuticals is more favorable than HUTCHMED.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score HUTCHMED 0 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Day One Biopharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 3.14 Do institutionals & insiders have more ownership in HCM or DAWN? 8.8% of HUTCHMED shares are held by institutional investors. Comparatively, 88.0% of Day One Biopharmaceuticals shares are held by institutional investors. 3.6% of HUTCHMED shares are held by insiders. Comparatively, 6.2% of Day One Biopharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Which has stronger valuation and earnings, HCM or DAWN? HUTCHMED has higher revenue and earnings than Day One Biopharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioHUTCHMED$630.20M4.74$37.73MN/AN/ADay One Biopharmaceuticals$131.16M5.12-$95.50M-$0.71-9.32 Is HCM or DAWN more profitable? HUTCHMED has a net margin of 0.00% compared to Day One Biopharmaceuticals' net margin of -42.66%. HUTCHMED's return on equity of 0.00% beat Day One Biopharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets HUTCHMEDN/A N/A N/A Day One Biopharmaceuticals -42.66%-14.98%-13.04% SummaryDay One Biopharmaceuticals beats HUTCHMED on 8 of the 15 factors compared between the two stocks. Get Day One Biopharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for DAWN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding DAWN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DAWN vs. The Competition Export to ExcelMetricDay One BiopharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$671.00M$2.93B$5.57B$9.32BDividend YieldN/A2.43%4.23%4.03%P/E Ratio-9.3220.5028.6419.75Price / Sales5.12267.15432.34182.50Price / CashN/A43.1536.0257.96Price / Book1.337.768.235.67Net Income-$95.50M-$55.11M$3.24B$257.98M7 Day Performance-5.43%1.03%0.05%0.56%1 Month Performance-0.30%8.54%5.65%8.88%1 Year Performance-58.65%-2.26%26.57%14.24% Day One Biopharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DAWNDay One Biopharmaceuticals2.4978 of 5 stars$6.62+0.8%$29.00+338.1%-58.2%$671.00M$131.16M-9.3260HCMHUTCHMED1.6212 of 5 stars$15.42-2.5%$19.00+23.2%-11.4%$2.76B$630.20M0.001,811Gap DownAMRXAmneal Pharmaceuticals2.5657 of 5 stars$8.41-0.1%$11.60+37.9%+12.1%$2.64B$2.79B-210.208,100CPRXCatalyst Pharmaceuticals4.8952 of 5 stars$20.95-2.4%$32.83+56.7%+25.1%$2.62B$491.73M13.3480Positive NewsBHCBausch Health Cos3.7697 of 5 stars$6.88-2.5%$7.42+7.8%-12.4%$2.61B$9.63B-62.5520,700OGNOrganon & Co.4.8128 of 5 stars$9.74-2.2%$18.00+84.8%-53.9%$2.59B$6.40B3.384,000Trending NewsXENEXenon Pharmaceuticals3.5727 of 5 stars$31.83-4.3%$54.82+72.2%-24.9%$2.55B$9.43M-9.85210Positive NewsMIRMMirum Pharmaceuticals3.2909 of 5 stars$50.47+0.3%$65.50+29.8%+31.7%$2.49B$336.89M-31.35140IBRXImmunityBio2.1392 of 5 stars$2.72flat$12.25+350.4%-56.9%$2.40B$14.74M-4.69590GMTXGemini TherapeuticsN/A$54.75+3.0%N/A+22.4%$2.37BN/A-54.7530News CoverageARWRArrowhead Pharmaceuticals3.5639 of 5 stars$16.84+0.3%$43.71+159.6%-38.9%$2.32B$3.55M-12.03400News Coverage Related Companies and Tools Related Companies HUTCHMED Competitors Amneal Pharmaceuticals Competitors Catalyst Pharmaceuticals Competitors Bausch Health Cos Competitors Organon & Co. Competitors Xenon Pharmaceuticals Competitors Mirum Pharmaceuticals Competitors ImmunityBio Competitors Gemini Therapeutics Competitors Arrowhead Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:DAWN) was last updated on 7/16/2025 by MarketBeat.com Staff From Our PartnersBank of America Says Gold Could Hit $4,000. Here How to Get Paid“I’ve always hated gold. It doesn’t pay dividends… it just sits there.” That’s what one income strategist b...Investors Alley | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredRevolutionary AI Tech Targets Early Diabetic Blindness Detection FDA Trial UnderwayTiny Stock, Massive Potential— this company’s AI platform is a game changer for healthcare!Interactive Offers | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | Sponsored[ATTENTION] This Crypto Rocket Is About Launch…Every crypto bull market ends with a final surge — the window where fortunes are made fast. According to tw...Crypto Swap Profits | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Day One Biopharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Day One Biopharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
